Sinopharm Of China Maxes Out IPO On Hong Kong Exchange
This article was originally published in PharmAsia News
Executive Summary
China's Sinopharm Group, the nation's largest distributor of pharmaceuticals, ended the purchase period for its initial public offering on the Hong Kong stock market by easily raising the maximum U.S.$1.13 billion